AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BOLT

Yonehiro Grant sold $44K of BOLT

Yonehiro Grant (Chief Operating Officer) sold 13,176 shares of Bolt Biotherapeutics, Inc. (BOLT) at an average of $3.32 ($3.24–$3.77) across 3 trades over 2026-09-16 to 2026-09-18.

Original reporting
SEC EDGAR · Yonehiro Grant
Published Sep 21, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The sale is modest and unlikely to affect market perception significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 21 2026

Background

Form 4 filing reports insider transactions to the SEC.

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

COO Yonehiro Grant sold 13,176 shares of Bolt Biotherapeutics for $43.8K in a Form 4 filing.

Expected impact

Limited short-term pressure; unlikely to move price materially.

Evidence & confidence

The transaction size ($44K) is small relative to market cap; market may view it as routine.

Market effects

Sector

No significant impact on biotech sector.

Regional

None.

Global

Minimal.

Counterpoint

What could challenge this read

Sale could be unrelated personal liquidity need; not a bearish signal.

Key entities

  • Company
    Bolt Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq (BOLT).

  • Person
    Yonehiro Grant

    Chief Operating Officer of Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

$BOLTHighAI 8/10

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de

SEC EDGAR 8-K
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K